Tectonic Therapeutic, Inc. (TECX) - Total Liabilities

Latest as of March 2026: $16.16 Million USD

Based on the latest financial reports, Tectonic Therapeutic, Inc. (TECX) has total liabilities worth $16.16 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check TECX asset resilience ratio to evaluate the company's liquid asset resilience ratio.

Tectonic Therapeutic, Inc. - Total Liabilities Trend (2016–2025)

This chart illustrates how Tectonic Therapeutic, Inc.'s total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see TECX total assets.

Tectonic Therapeutic, Inc. Competitors by Total Liabilities

The table below lists competitors of Tectonic Therapeutic, Inc. ranked by their total liabilities.

Company Country Total Liabilities
Sunrise Energy Metals Ltd
AU:SRL
Australia AU$1.37 Million
Capital Bancorp
NASDAQ:CBNK
USA $3.40 Billion
Guangdong Dp Co Ltd
SHE:300808
China CN¥204.21 Million
Unizyx Holding Corp
TW:3704
Taiwan NT$16.61 Billion
AGI Greenpac Limited
NSE:AGI
India Rs-24.07 Billion
Jiangsu Hengshang Energy Conservation Technology Co. Ltd. A
SHG:603137
China CN¥1.63 Billion
OPTHEA LTD (SP.ADR/8)
F:UKJ2
Germany €314.48 Million
Kunshan Asia Aroma Corp. Ltd.
SHE:301220
China CN¥682.01 Million

Liability Composition Analysis (2016–2025)

This chart breaks down Tectonic Therapeutic, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Tectonic Therapeutic, Inc. balance sheet independence to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 18.51 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.07 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.07 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Tectonic Therapeutic, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Tectonic Therapeutic, Inc. (2016–2025)

The table below shows the annual total liabilities of Tectonic Therapeutic, Inc. from 2016 to 2025.

Year Total Liabilities Change
2025-12-31 $9.71 Million -19.95%
2024-12-31 $12.13 Million -90.22%
2023-12-31 $124.03 Million +33.57%
2022-12-31 $92.86 Million +94.12%
2021-12-31 $47.84 Million +183.23%
2020-12-31 $16.89 Million +16.47%
2019-12-31 $14.50 Million +28.38%
2018-12-31 $11.29 Million +208.86%
2017-12-31 $3.66 Million +273.54%
2016-12-31 $979.00K --

About Tectonic Therapeutic, Inc.

NASDAQ:TECX USA Biotechnology
Market Cap
$513.43 Million
Market Cap Rank
#12203 Global
#3058 in USA
Share Price
$27.21
Change (1 day)
-2.51%
52-Week Range
$14.71 - $37.93
All Time High
$54.84
About

Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's lead product is TX45, a Fc-relaxin fusion molecule that activates the RX… Read more